{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'Administer (by subject or trained caregiver) IMP with the elamipretide delivery', 'system, recording the location, date, and time of the IMP administration in the', 'electronic or paper diary.', 'Assess for ISR 30 (+5) minutes after the IMP administration with the elamipretide', 'delivery system (as described in Section 6.3.15).', '6.2.1.3.', 'Double-Blind Treatment Period', 'Complete the PMMSA (as described in Section 6.3.8 and as outlined in Appendix 13)', 'daily during Treatment Period.', 'Subjects (or trained caregivers) will administer IMP with the elamipretide delivery', 'system, recording the location, date, and time of the IMP administration in the', 'electronic or paper diary.', '6.2.1.4.', 'Week 4 (Day 29 =2), Week 12 (Day 85 4), and Week 24 (Day 169 +14 days)', 'Visits', 'NOTE: The 6MWT must be completed after all other trial assessments. On days of trial', 'visits, the IMP should be administered at the clinical site. At the Week 4, Week 12, and Week 24', 'Visits, the IMP administration should occur after all other trial procedures. At the Week 24 Visit,', 'IMP administration will only occur if the subject is continuing to PART 2 of the SPIMM-301', 'trial.', 'Collect all used IMP supplies (Week 4 and Week 12 Visits) and all trial-related', 'supplies in addition to all elamipretide delivery system supplies (Week 24 Visit) and', 'assess compliance.', 'Provide new IMP supplies (Week 4 and Week 12). At the Week 24 Visit, if the', 'subject is continuing to PART 2, provide new elamipretide delivery system supplies.', 'Update concomitant medication/procedures (including supplements and vitamins)', 'during the Treatment Period (as described in Section 6.3.1).', 'Assess AEs/ADEs.', 'Complete a physical examination (as described in Section 6.3.2).', 'Collect vital signs (as described in Section 6.3.4).', 'Complete 12-lead resting ECG (as described in Section 6.3.5).', 'Complete the C-SSRS \"Since Last Visit\" (as described in Section 6.3.3 and provided', 'in Appendix 6).', 'Draw blood and collect urine for clinical laboratory testing and urinalysis as outlined', 'in Appendix 4 (and as described in Section 6.3.6). At the Week 24 Visit, an additional', 'blood sample will be collected and stored for assessing the immunogenicity potential', 'of the IMP.', 'Draw blood for PK testing as described in Section 6.3.14:', '- Week 4: 1 hour post dose ( 10 min)', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '44']['SPIMM-301 Version 4.0', '15 June 2018', '- Week 12:30 min, 2 hours, and 4 hours post dose ( 10 min)', '-', 'Week 24: pre-dose (-10 min)', 'Complete the PMMSA (as described in Section 6.3.8 and as outlined in Appendix 8)', 'and collect results in the electronic or paper diary. The PMMSA should be completed', 'daily during the Treatment Period.', 'Complete the Neuro-QoL Fatigue (as described in Section 6.3.9 and as provided in', 'Appendix 9).', 'Complete the EQ-5D-5L (as described in Section 6.3.10 and as provided in', 'Appendix 10).', 'Complete the Patient Global Impression (PGI) Scales (as described in Section 6.3.11', 'and as provided in Appendix 11).', 'Complete the Clinician Global Impression (CGI) Scales (as described in', 'Section 6.3.12 and as provided in Appendix 12).', 'Conduct the 6MWT (as described in Section 6.3.13 and as outlined in Appendix 13).', 'Administer (by subject or trained caregiver) IMP with the elamipretide delivery', 'system, recording the location, date, and time of the IMP administration in the', 'electronic or paper diary. This is not performed at Week 24 Visit unless the subject is', 'continuing into PART 2. If the subject continues into PART 2, the subject will', 'continue (or start, for subjects treated with placebo in PART 1) elamipretide therapy', 'the day of the Week 24 Visit (using the PART 2 supply of IMP).', 'Note: Administration of PART 2 IMP at the Week 24 Visit is the start of PART 2', 'Treatment Period.', 'Assess for ISR 30 (+5) minutes after the IMP administration with the elamipretide', 'delivery system (as described in Section 6.3.15). This is not performed at Week 24', 'Visit unless the subject is continuing into PART 2.', 'Remind women of childbearing potential and male subjects with female partners of', 'child-bearing potential to use a highly effective method of contraception until 28 days', 'after the last dose of IMP (Week 24 Visit).', 'Review all PART 2 Continuation Criteria (Week 24 Visit).', 'Schedule next center visit:', '- Post-treatment follow-up visit for subjects not continuing into PART 2.', '-', 'Week 28 visit for subjects continuing into PART 2.', '6.2.1.5.', 'PART 1 Post-Treatment Follow-Up Period (4 weeks [+7 days])', 'At the Week 24 Visit, the subject and the Investigator will determine whether the subject will', 'continue into PART 2 (confirming the subject meeting the Continuation Criteria). Subjects who', 'will not continue into PART 2 will complete the PART 1 Follow-Up Period and PART 1 End-of-', 'Trial Visit.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '45']\n\n###\n\n", "completion": "END"}